Some ten years ago the harbingers of doom were savouring the approach of 1984 with its connotations of George Orwell's Big Brother and all that that concept stood for. Now, before the arrival ofthe second millenium, there is the prospect, in 1992, ofthe single European market and Brussel's bureaucracy to unnerve the innocent. At a meeting in May of the Library and Scientific Research Section an attempt was made to divine the effect of European harmonization on the monitoring of medicines with contributors from the British regulatory authority and from the pharmaceutical industry in France and the United Kingdom.
Current practice in the EEC The first speaker, Dr Susan Wood of the Medicines Control Agency in London, started from the standpoint of the British Government, which envisages post-1992 Europe as a confederation of sovereign states, by stating that it will be necessary for each country in the EEC to have a procedure for monitoring the safety of medicines. It will also be necessary to have collaboration and rapid communication between member nations so that information can be exchanged and appropriate action taken in concert and without delay.
At present, diverse methods operate among member nations. Spontaneous adverse drug reaction (ADR) reporting schemes operate in 10 of the 12 countries but the type of information collected, its classification and its origins differ; reporting is obligatory in two of the 10 countries. Post-marketing surveillance and epidemiological studies are carried out by about half the member nations but prescription event monitoring (PEM) and linkage of medical records with the use of medicines has only been attempted in the United Kingdom. Thus, there is considerable room for harmonization of practices to enable reliable information to be collected and exchanged.
Existing collaborative ventures
About 20 years ago a programme for international medicines monitoring was established under the auspices of the World Health Organization. The Collaborating Centre for International Drug Monitoring is now based in Sweden, at Uppsala, and receives spontaneously reported ADRs from 26 countries. This ADR data base is now accessible through on-line computer links to member countries of the WHO.
Another collaborative undertaking was the establishment, in 1985, of an ADR Working Group supported by the Centre for International Organizations of Medical Sciences (CIOMS). This ADR working group has representatives from six regulatory authorities and seven pharmaceutical companies. They have agreed common definitions and methods for reporting serious suspected ADRs. As a result, the CIOMS procedures have been adopted by many countries involved in the ADR working group so improving the quality of information and the speed ofcommunication between ph til manufac and regulatory authorities.
Future harmonization within the EEC On the assumption that spontaneous ADR reporting schemes are likely to remain the mainstay for monitoring the safety of medicines, much remains to be done to agree definitions and procedures and to improve the quality of information and reporting before the single market in medicines arrives in 1992. The EEC should capitalize on existing collaborative schemes.
Computerization of data is indispensible for monitoring safety but its classification needs to be refined and agreed before the effectiveness of pan-European cooperation can eventuate. It will also be necessary to take into account differences in medical practice and culture between member nations as these will undoubtedly affect the type and frequency of ADRs which are reported. It was the opinion of Dr Wood that the collection, assessment, analysis and interpretation of ADR information should continue to be done nationally. Each country would then contribute its experience to a central organization to identify hazards and to take appropriate action. The first step in this direction was taken earlier this year with the establishment of a Pharmacovigilance Working Group of the Committee on Proprietary Medicinal Products (CPMP).
With the exception ofEEC Council Directive 75/319, Article 33, which requires member nations to notify each other of information relevant to continuing to authorize the marketing of a medicine, Council Directives have not so far been addressed specifically to post-marketing surveillance and the safety of medicines. This situation is bound to change. The difficulties of reaching agreement and achieving common standards of practice were mentioned by Dr Wood but they were illustrated in greater detail by the two subsequent speakers, Dr C Benichou of Roussel Uclaf in Paris and Dr B A Hurn of the Wellcome Research Laboratories in Beckenham, who dealt with the present state of affairs in France and the United Kingdom.
Medicines monitoring in France
France is one European country where ADR reporting is obligatory for prescribers as well as for the pharmaceutical industry. Prescribers must report ADRs to their regional centre whereas the pharmaceutical industry is required to assess each case for a causal relationship according to an official method before communicating reports to the National Commission of Pharmacovigilance at the Ministry of Health.
There are 30 regional centres (CRPVs) each of which is located in a university hospital, usually in the department of pharmacology. The centre has a director and a team of up to six doctors and pharmacists. The centre is financed jointly by the Ministry of Health, the hospital in which it is located, the Ministry of Education and by other public or private funding. The regional centres have a three-fold function: to collect data on ADRs; to inform prescribers and the pharmaceutical industry about ADRs; and to carry out research on ADRs and other problems related to medicines. The National Commission of Pharmacovigilance is responsible for the national data bank of ADRs. An on-line service to the central computerized data bank The Royal Society of Medicine is provided to all regional centres both for entering data, including the assessment of causality, and for the output of information. The directors of the regional centres meet in Paris on alternate months as part of a central technical committee. This committee has the power to evaluate ADRs, initiate validation studies, consult with experts and report to the National Commission. The pharmaceutical industry is required to report ADRs, including foreign experience, to the National Commission every 6 months on new medicines during their first year of availability and subsequently every year. The causal relationship has to be assessed according to the official method before the ADR is reported. More than half of all notifications are sent in by the pharmaceutical industry.
Each ADR is evaluated with decision tables, separately for chronology and clinical criteria, and afterwards with a final combined decision table to assign to each ADR one of five evaluations; unlikely, dubious, possible, probable, highly probable. Laboratory information is also taken into consideration in deciding on causality. Dr Benichou gave several illustrations ofthe assessment of causality using the French system.
Medicines monitoring in the United Kingdom
Spontaneous reporting of ADRs, as practised in the UK with 'yellow cards', is likely to continue because it has certain advantages, including exposure of a large population to medicines, coverage of all prescribed medicines and the reporting of all types of reactions. Such schemes have the capability of detecting rare events and of giving early warning of problems. Dr Hurn's misgivings about the scheme in the UK were that case follow-up is sometimes inadequate and the Medicines Control Agency does not share its data with pharmaceutical companies; confidentiality, which is usually given as the reason for secrecy, is not a real problem as the confidential elements can be omitted from reports made to pharmaceutical companies. Indeed, ASPP (Anonymised Single Patient Prints) reports have now become available from the Medicines Control Agency on electronic discs ready for transfer to a computer store.
Dr Hurn described the system for handling spontaneous reports of ADRs at Wellcome which, as in other large pharmaceutical companies, comprises a large data base on a mainframe computer which holds information on ADRs reported from all their operating companies and which is rapidly searchable. However, this requires a large central resource to enter the data since the accuracy and quality of the coding of the data is crucial to subsequent searching and retrieval of information.
Although it is recognized that there is underreporting of ADRs, Dr Hurn did not consider this to be a problem in a population as large as that in the United Kingdom. His concern was of unknown variation in ADR reporting rates between medicines and events. Also, the quality of individual reports is often poor, and insufficient to assess causality. Both of these factors affect the 'numerator', that is, the number of patients known to have suffered an adverse event, but the 'denominator', the number of patients treated with the medicine, is unknown. An estimate can be made from sales data using a standard dose and duration oftreatment but, at best, such an estimate is a very rough approximation. Thus, there is uncertainty with both the numerator and the denominator which makes it impossible to determine an incidence, make valid comparisons and evaluate risk in relation to benefit. Pharmacoepidemiological studies designed specifically to resolve such issues are still unable to determine causality.
It might seem an elementary point but it is vital, when considering a prospective monitoring study, to decide what question is being asked about a particular medicine. Some surveillance studies are carried out on cohorts of 10 000 patients, or fewer, and uncommon serious adverse reactions are unlikely to be detected by such investigations. Furthermore, prospective studies on such large numbers are unable to be completed rapidly and are inappropriate for confniring potentially serious problems revealed through spontaneous reporting. Therefore, one needs to decide what information will be needed to answer the question and what is the best source for the data considering that accuracy and completeness are essential to make the study capable of interpretation.
The ideal data resource is one that can be approached cautiously, with due regard for the pitfalls. It needs to be easily and cheaply accessible and the data need to be organized in some convenient form. There should be a well rehearsed routine for collecting or selecting data. It is important that the resource should be under expert management, preferably independent of the principal interested parties, the regulatory authorities and the pharmaceutical industry. Pharmacoepidemiology is not a job for amateurs, said Dr Hurn.
Spontaneous ADR reporting on yellow cards will obviously continue as at present. Prescription Event Monitoring (PEM) at the Drug Safety Research Unit at Southampton will become a more valuable resource as computerization at the Prescription Pricing Authority (PPA), on which PEM relies, allows more medicines to be monitored. However, the scheme will not detect rare adverse reactions. The installation of microcomputers in general practices, which are linked to a central coordinator such as VAMP or AAH Meditel, will make feasible prospective as well as retrospective studies by GPs on large populations of patients. The Medicines Evaluation and Monitoring Group (MEMO) in Dundee has developed an automated record-linkage system of outpatient prescription information related to outcome data on hospital inpatients through the use of a unique personal identifier, such as exists in some of the American record-linkage schemes of the Health Maintenance Organizations. However, MEMO requires considerable manual input and its lack of funding means that it is only really suitable for studying specifically selected medicines. Record linkage may be developed through the use of 'smart cards' which are the subject of experiments in South Wales.
The meeting heard about the lack of uniformity in ADR monitoring throughout the EEC and the steps being taken to rationalize the reporting and evaluation of spontaneous events by member nations. The French system of regional centres with a central co-ordinating organization could become the pattern for member nations and a central CPMP-like group. However, experience in the United Kingdom illustrates the limitations of spontaneous ADR reporting and the possibilities of exploiting the National Health Service with computer-based recordlinkage schemes to provide a data base of many millions of patients and good interpretable data on which to base rational decisions. Perhaps only then will the alarms generated by the present spontaneous reporting schemes become a thing of the past.
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Transsexuality
The views of Mrs Somerset in her letter (August 1989, JRSM, p 509) challenge those of us who recommend gender reassignment for some transsexual patients. The views require reply. The belief that transsexualism is a coping device to absolve guilt over homosexual inclination is not supported by the considerable literature on the subject. Certainly the outcome of gender reassignment may be poor, especially if doctors are prevailed upon to undertake these proceedings without full observation and allowance oftime to assess the patient's ability to live in, and be accepted in, the gender role to which they aspire. However there is a proportion of applicants for gender change who can do so and for these people their quality of life will be improved by gender reassignment. I wrote' that assessemnt of outcome be undertaken independently of the clinical team and I now report an outcome study undertaken by Mr A Butler, Senior Lecturer in Mental Health Social Work at the University of Leeds. Mr Butler fulfilled the criteria for independence and lack of bias for or against gender reassignment. He reported on the first five consecutive male to female patients who had proceeded through all stages of reassignment including vaginoplasty, since the establishment ofthe Gender Identity Clinic at Leeds. His assessment was made at the patients' homes about a year following operation. The essential findings are: (1) all patients expressed satisfaction with the procedures including the surgical result; (2) no patient showed evidence of emotional instability; (3) four ofthe five had improved in social relationships and self-confidence; two of the five had broken offrelationship with their family prior to referral to the Clinic but, for those who remained in contact, all stated an improvement in the quality of their relationship. This report of our interventions gave us confidence to continue with the difficult procedures of reassignment; to fail to provide such facilities for suitable patients is a failure to relieve remediable distress. To the discussion on transsexuality between Dr Armstrong (February 1989 JRSM, p 103) and Mrs Somerset (August 1989 JRSM, p 508), I wish to contribute a very old legal point of view which is to be found in para 19-23 of General Commmon Law for the Prussian States new edn 1806; Berlin: G C Nauck, namely: para 19. Iftranssexuals are born the parents choose which sex the children will have during their education. para 20. That person will be at liberty after completing their 18th year to select which sex he/she will hold in future. para 21. After this decision his/her rights will be judged accordingly in future. para 22. If the rights of a third party are involved by the transsexual's sex decision, this third party can insist on an investigation by an expert. para 23. The expert's finding is made independently of the transsexual's or the parents decision. I think this regulation per legem has been very wise as well as intelligent. Having served the NHS since its foundation, and having made small contributions here and there to the technological achievements of our organization, it makes me proud to read about the improvements we have produced since that primitive era. It is surely a matter for congratulation that BUPA can examine 10 400 workers aged 25-44 years (Daily Mail, 29 October 1988) and report that only 83% of males and 75% of women are unfit; no more than 30% of all employees have dangerously high cholesterol levels; and that blood pressure, alcohol problems and lack of exercise are rated no higher than rife today.
What on earth would have been our condition without the NHS? P G F NIXON Consultant Cardiologist Charing Cross Hospital, London
